Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin as Adjunctive Therapy to Buprenorphine for Opioid Use Disorder
NCT06067737Phase 2Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Feb 2024
- Primary completion
- Jul 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in opioid use disorder (OUD), sponsored by Johns Hopkins University. Started Feb 2024; status: recruiting.
02
Drugs
psilocybin
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT06067737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067737.